Aridis Pharmaceuticals Inc (NASDAQ:ARDS) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totalling 10,600 shares, a drop of 19.7% from the June 30th total of 13,200 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 3,700 shares, the days-to-cover ratio is currently 2.9 days.
ARDS stock traded down $0.24 during mid-day trading on Wednesday, reaching $8.15. The company had a trading volume of 4,412 shares, compared to its average volume of 3,946. The stock’s 50 day moving average is $9.64. The company has a market capitalization of $66.08 million and a P/E ratio of -1.16. Aridis Pharmaceuticals has a 52 week low of $6.91 and a 52 week high of $13.85.
Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its quarterly earnings results on Monday, August 12th. The company reported ($1.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.19). Aridis Pharmaceuticals had a negative net margin of 660.78% and a negative return on equity of 1,961.31%. On average, sell-side analysts predict that Aridis Pharmaceuticals will post -3.11 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on ARDS shares. Zacks Investment Research upgraded Aridis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. ValuEngine upgraded Aridis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Maxim Group restated a “buy” rating on shares of Aridis Pharmaceuticals in a research note on Wednesday, July 31st. Finally, Northland Securities restated a “buy” rating and issued a $40.00 price target on shares of Aridis Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $27.50.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Recommended Story: What are catch-up contributions?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.